Clinical Trial Detail

NCT ID NCT03122496
Title Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

thyroid gland cancer

Therapies

Durvalumab + Tremelimumab

Age Groups: senior adult

No variant requirements are available.